App Engagement in Pharmaceutical Marketing

Introduction: Mobile applications have become an important channel in pharmaceutical marketing, providing tools and services that go “beyond the pill” to support patients and healthcare professionals. Pharma companies increasingly use apps to improve medication adherence, educate patients and providers, and gather real-world data. This report provides a comprehensive overview of how pharma is leveraging mobile apps, the trends driving their use, strategic objectives behind app development, engagement strategies for success, metrics for measuring impact, key challenges (including regulatory and privacy hurdles), case studies of successful apps, and future innovations shaping the landscape.

Mobile apps allow patients to manage medications and health data on their smartphones, improving engagement in treatment.

Overview: How Pharma Uses Mobile Apps in Marketing

Pharmaceutical companies employ mobile apps in a variety of ways to enhance marketing and patient support. Branded “companion” apps are often paired with specific prescription drugs, offering features like medication reminders, dose tracking, symptom logging, and patient education content pmlive.com pmlive.com. These apps are designed to accompany a patient through their treatment journey – from initial awareness and disease education to ongoing adherence and self-management. For example, a companion app for an injectable medication might include injection training videos and dose calculators to help patients administer therapy correctly geneticdigital.co.uk. Some apps facilitate patient–provider communication, enabling users to share health data or receive telehealth consultations with healthcare professionals (HCPs) digitalya.co. Other pharma apps focus on disease education and awareness, providing general health information or tools to help patients understand their condition, often in service of building trust and supporting better outcomes.

In addition to patient-facing tools, pharma companies have developed HCP engagement apps and portals to support healthcare professionals. These may include mobile reference apps with drug information, clinical guidelines, or continuing medical education content, as well as portals that allow HCPs to receive updates on new therapies or engage with pharmaceutical reps through digital channels. The goal is to integrate pharma into HCPs’ digital workflows. In one case, a global pharma company launched an HCP engagement platform (accessible via web and mobile) and achieved over 100,000 downloads by physicians, significantly boosting digital touchpoints with prescribers indegene.com. Such HCP-focused apps aim to strengthen relationships with providers by offering convenient access to resources and improving communication (for instance, enabling doctors to request samples or patient materials through an app rather than traditional channels).

Patient support and adherence apps are a particularly common category. These range from general medication management apps to drug-specific programs. For example, some pharma companies offer patient adherence apps that remind users to take their medication on schedule, track their doses, and alert them when refills are due deloitte.com pmlive.com. By providing these supportive services, the pharmaceutical brand positions itself as a partner in the patient’s care rather than just a pill supplier. Many modern companion apps also integrate interactive elements such as symptom checkers or mood trackers, and they can securely share patient-reported data with HCPs to inform treatment decisions pmlive.com. Overall, the use of mobile apps in pharma marketing represents a shift toward more patient-centric, service-oriented strategies – often described as part of the “beyond the pill” movement – wherein the medication is supplemented by digital tools that enhance the treatment experience pmlive.com pmlive.com.

Key Trends in Pharma Mobile App Engagement

Several key trends are shaping the use and impact of mobile apps in the pharmaceutical sector:

• Rising Adoption of Digital Health Tools: In recent years there has been a surge in digital health app usage by consumers. A Morning Consult survey found about 40% of adults now use mobile health apps and 35% use wearable devices to manage their health geneticdigital.co.uk. This growing comfort with health technology creates an opportunity for pharma companies to integrate digital solutions with their products. Patients increasingly expect tech-enabled support as part of therapy, prompting pharma to build comprehensive “patient support ecosystems” that extend beyond just selling a drug pmlive.com.

• Acceleration Due to COVID-19: The COVID-19 pandemic was a major catalyst for digital health adoption. Telehealth and remote patient monitoring expanded rapidly during lockdowns. For instance, the UK’s NHS saw a 90% uptake in remote consultations at the height of the pandemic geneticdigital.co.uk. Pharma companies, in turn, accelerated their digital transformation efforts during this time. The pandemic highlighted the value of apps for maintaining continuity of care when in-person visits are limited pmlive.com. It also spurred regulatory innovation – notably in Germany, which launched the DiGA (Digital Health Applications) program in 2020. Under DiGA, doctors can prescribe certified health apps that are reimbursed by insurance. As of 2023, over 20 such DiGA apps have been approved for conditions ranging from diabetes to mental health geneticdigital.co.uk. This trend of reimbursable digital therapeutics demonstrates a path for pharma: integrating apps into standard care with payer support. Other countries are now evaluating similar models, though adoption varies (the UK, for example, is still evolving its integration of digital apps into healthcare, lagging behind Germany in formal reimbursement pathways geneticdigital.co.uk).

• Proliferation of Disease-Specific Apps and Digital Therapeutics: The overall digital health app landscape has exploded. By late 2024, an estimated 337,000 health apps were available across app stores drugstorenews.com. Many of these are disease-specific apps that go beyond general wellness, targeting chronic conditions and specific patient needs. Within this universe, a new class of evidence-based tools known as prescription digital therapeutics (PDTs) has emerged. More than 360 software-based therapeutic products are now commercially available, including about 140 FDA-approved or CE-marked digital therapeutics for use at home, and another 220 used in clinical or care settings drugstorenews.com. Pharmaceutical companies are actively partnering in this space – for example, Novartis partnered with digital therapy startup Kaiku Health to develop a tool for monitoring oncology patients deloitte.com, and Pfizer partnered with Alex Therapeutics on a digital smoking cessation program in Germany deloitte.com. The trend shows pharma’s growing interest in “software as medicine” to complement drug therapies. However, it’s worth noting that commercial uptake of digital therapeutics has faced challenges (discussed later), even as the number of products grows.

• Data and Partnerships Driving Innovation: Pharma companies recognize that they often lack native app development expertise, so partnerships and acquisitions are a key trend. Many top pharma firms have struck alliances with health-tech companies to co-develop apps or have acquired digital health startups outright deloitte.com deloitte.com. Examples include Sanofi’s partnership with Health2Sync for diabetes management, Pfizer’s acquisition of ResApp Health (an app using AI to diagnose respiratory illness via cough sounds), and Roche’s earlier acquisition of MySugr (a diabetes management app) deloitte.com deloitte.com. These deals bring in technology know-how and ready-made platforms. They also signal that pharma views digital solutions as integral to their future offerings. Additionally, real-world data collected through apps is increasingly valuable – companies are using patient-generated data to understand real-world treatment patterns, outcomes, and even to detect rare side effects, thus feeding into pharmacovigilance and evidence generation deloitte.com deloitte.com. The integration of app data with real-world evidence efforts is a strong trend, aligning with the broader shift toward value-based care and outcomes measurement.

• Personalization and AI: A notable trend is the use of artificial intelligence and machine learning to personalize the app experience. Apps can leverage AI to deliver tailored content (for example, adjusting educational materials to a patient’s literacy level or predicting when a patient might miss a dose and sending proactive reminders). Pharma marketers see AI-driven personalization as a way to increase engagement by making interventions more timely and relevant digitalya.co digitalya.co. Moreover, AI chatbots or virtual health assistants are being piloted within some companion apps to answer patient questions about their medication or condition 24/7. The expectation is that AI can improve user engagement by providing interactive support and coaching. The future trend (discussed later) extends this to more advanced AI that could adapt interventions based on a user’s behavior patterns in the app.

• Regulatory Evolution: Regulators are acknowledging the growing role of digital health. The FDA in the U.S. released draft guidance on Prescription Drug-Use-Related Software (PDURS), which provides a framework for companion apps that accompany medications pmlive.com geneticdigital.co.uk. This guidance differentiates between software functions that are part of a drug’s labeling (and thus have direct clinical impact) versus those that are considered promotional or supportive. Similarly, in Europe, frameworks like the EU’s Medical Device Regulation (MDR) and country-specific pathways (e.g. Germany’s DiGA, UK’s NHS DTAC standards) are shaping how pharma develops apps (more on this in a dedicated section). The trend is toward clearer pathways for approval and even reimbursement of digital health tools, which in turn encourages pharma to invest in higher-quality, clinically validated apps.

In summary, mobile app engagement in pharma is being driven by the convergence of increased consumer adoption of health tech, the impetus from COVID-19 to find digital solutions, regulatory support for digital therapies, and pharma’s strategic partnerships in the tech space. Apps are becoming a normal extension of pharmaceutical products, and keeping abreast of these trends is essential for pharma marketing teams aiming to remain competitive and patient-centric pmlive.com geneticdigital.co.uk.

Strategic Objectives for Pharma-App Initiatives

Pharma companies typically pursue several strategic objectives when developing mobile apps as part of their marketing and patient support strategy:

• Improving Medication Adherence and Outcomes: The foremost goal is often to help patients take their medications as prescribed, thereby improving health outcomes. Non-adherence to therapy is a longstanding problem – between 25% and 50% of patients globally do not follow their prescribed treatment plans, leading to poor outcomes and substantial avoidable costs revolve.healthcare. By providing medication reminders, alerts for missed doses, and user-friendly tracking, companion apps seek to boost adherence rates. Better adherence not only benefits patients (fewer disease complications, hospitalizations, etc.) but also benefits pharma by maximizing the effectiveness of their therapies and potentially increasing prescription refills. For example, engaged patients who use an app are more likely to take medications on time, which can translate into longer persistence on therapy revolve.healthcare revolve.healthcare. One Deloitte analysis estimates that improved adherence and earlier treatment engagement via companion apps can increase the sales volume of a medication by 3% to 20% depending on the disease area deloitte.com deloitte.com. In essence, helping patients stick with treatment is a win–win: it improves clinical outcomes and bolsters the product’s commercial performance.

• Enhancing Patient Engagement and Satisfaction: Beyond adherence, pharma aims to create a positive patient experience with their brand. Apps offer a channel for value-added services – such as disease education, lifestyle tips, coaching, and progress tracking – which can increase a patient’s sense of support. A strategic objective is to foster a stronger emotional connection and brand loyalty. If a patient feels the app provided by a pharma company genuinely helps them manage their condition, they may develop greater trust in that company and its products geneticdigital.co.uk. Especially in competitive therapeutic areas, a high-quality app can differentiate a brand. For instance, two medications might be similar in efficacy, but if one comes with a superior companion app (interactive tools, 24/7 support line, etc.), patients and providers may favor it for the added support. Over time, this can improve patient retention on therapy – patients are less likely to abandon treatment if they feel supported – and preserve market share for the brand.

• Collecting Real-World Data and Insights: Many pharma apps double as data collection tools (with patient consent). A strategic goal for companies is to gather real-world evidence (RWE) on how patients use their medication and respond to it outside of clinical trials deloitte.com. Apps can capture data on dosage timing, symptom fluctuations, side effects, and even patient-reported outcomes or quality-of-life metrics. This information is incredibly valuable for multiple reasons: it can inform better understanding of the product’s performance, support pharmacovigilance (by flagging adverse events or rare side effects earlier) deloitte.com, and provide evidence of value to payers (e.g. demonstrating that use of the app + drug leads to measurable improvements in outcomes or adherence). Pharma companies are increasingly interested in leveraging these insights to refine their strategies. Additionally, having a direct digital connection to patients allows companies to conduct surveys or gather feedback, guiding patient-centric improvements in products or support programs.

• Extending the Treatment Ecosystem (“Beyond the Pill”): Strategically, apps allow pharma companies to position themselves not just as drug manufacturers but as holistic health solution providers. This is often termed the “beyond the pill” strategy – delivering services around the core drug product pmlive.com. By offering a companion app, pharma demonstrates a commitment to patients’ overall therapy journey, including aspects like education, behavior change, and emotional support. This can improve the overall patient experience and outcomes, aligning with healthcare systems’ shift toward outcome-based care. It can also address specific unmet needs in a disease area. For example, in chronic diseases where day-to-day self-management is critical (diabetes, asthma, depression, etc.), pharma-provided apps can fill gaps in between doctor visits, coaching patients on lifestyle or providing psychological encouragement. Strategically, this approach can also help pharma companies to differentiate their product in crowded markets or as patents expire. Offering a robust companion app can be a way to add value to a branded drug even when generic competitors emerge revolve.healthcare revolve.healthcare. Essentially, the app becomes part of the product’s value proposition.

• Strengthening HCP Relationships and Brand Image: Another objective is to improve engagement with healthcare professionals. Apps that facilitate HCP–patient connections (for instance, allowing doctors to monitor patient data or adjust treatment remotely) can increase physicians’ confidence in prescribing a particular therapy. Pharma companies also develop HCP-centric apps (or app features) to provide decision support or convenient access to information. By doing so, they aim to become a go-to resource for clinicians, which can translate into better product advocacy. For example, a pharma company might include an HCP portal in the app where clinicians can view their patients’ adherence data (with permission) or download patient education brochures to share. This not only saves the HCP time but also reinforces the utility of the pharma’s support program. Additionally, on the marketing side, having digital channels to HCPs (like push notifications about new clinical data or dosage calculators in the app) helps maintain mindshare in an era where sales reps have less face-to-face access. In summary, a strategic aim is to use apps to deliver more personalized, useful interactions with HCPs, which supports the overall brand relationship geneticdigital.co.uk revolve.healthcare.

• Facilitating Market Differentiation and Product Uptake: When implemented well, apps can drive competitive advantage. This can manifest as increased uptake of a therapy (if an app helps patients get started and stay on therapy longer) or as a selling point in market access discussions. Payers and healthcare providers are more likely to favor treatments that come with tools improving adherence and outcomes, due to potential cost savings (fewer hospitalizations, better disease control) revolve.healthcare revolve.healthcare. For instance, if a pharma demonstrates that patients using their drug + app have significantly higher adherence and a reduction in emergency visits, that data can be used in formulary negotiations or value-based contracts. Thus, one objective is to create measurable clinical and economic benefits through app companion programs, strengthening the drug’s value proposition. Furthermore, apps can help pharma companies reach previously underserved patient populations by lowering barriers (geography, education) through digital means deloitte.com deloitte.com. By extending reach and improving outcomes, pharma can indirectly boost medication sales in a patient-centric way. Indeed, industry analyses suggest that digital companions primarily augment revenue indirectly by supporting the core drug business (rather than being revenue-generating products themselves) deloitte.com.

In summary, pharmaceutical marketers view mobile apps as strategic tools to improve adherence, enrich the patient and provider experience, differentiate their therapies, and gather data – all of which ultimately support both better health outcomes and business outcomes. As one industry report put it, pharma’s interest in digital health is driven by the need to enhance revenue streams amid slowing R&D returns, and apps are one avenue to provide complementary support that can extend treatment duration and patient reach deloitte.com.

Engagement Strategies in Successful Pharma Apps

Developing an app is only part of the challenge – ensuring that patients (or HCPs) actively use and derive value from the app is critical. Successful pharma apps employ a range of engagement strategies to keep users interested, motivated, and returning regularly. Key engagement techniques include:

• Gamification and Rewards: Introducing game-like elements can significantly boost user motivation and long-term engagement. Many pharma companion apps use points, badges, or challenges to reward adherence and healthy behaviors. For example, the diabetes app mySugr incorporates a points system for logging blood sugars and completing daily tasks; this gamified approach increased user adherence to the app by 85% over a three-month period digitalya.co. Gamification taps into users’ natural desire for achievement and feedback. Patients might earn badges for taking their medication on time for a full week, or accumulate points that can be redeemed for educational resources or small incentives. Such reward systems make the routine of disease management more engaging. Another example is Re-Mission, a game designed for young cancer patients where players “blast” cancer cells; studies showed that playing Re-Mission improved patients’ treatment adherence and motivation, correlating with better adherence to chemotherapy in real life digitalya.co. Overall, gamification transforms adherence into something more interactive and fun, countering the monotony or stress of chronic disease management revolve.healthcare.

• Personalized Coaching and Reminders: Personalization is a powerful engagement tactic. Apps that tailor content and reminders to the individual see higher engagement. Personalized medication schedules – for instance, allowing the user to set custom reminder times or providing dosing alerts that fit their daily routine – help ensure the app fits seamlessly into a patient’s life digitalya.co. Beyond basic reminders, many apps now offer personalized health tips, insights, and feedback. For example, an app might analyze a patient’s logged symptoms and send a message like, “It looks like your asthma symptoms are worse on weekends – don’t forget to use your inhaler before activity on those days,” along with educational content. Such tailored insights make the app feel like a personal coach. They also promote self-awareness in patients, helping them see the connection between their actions and health. Data visualization (charts of progress, symptom trends) further personalizes the experience by giving users feedback on how they’re doing. This strategy leverages behavioral science: seeing progress or patterns can reinforce positive behaviors and keep users engaged in their care.

• Community and Support Features: Successful apps often foster a sense of community or support, which can be incredibly engaging for users. In-app support groups or forums allow patients to connect with others who have the same condition, share experiences, and exchange tips. This peer support can reduce the feeling of isolation and increase an individual’s commitment to the app (and by extension, their treatment). Some pharma apps host moderated community discussions or patient ambassador stories to inspire users. Additionally, providing secure messaging with healthcare professionals or pharmacists within the app is a strong engagement driver digitalya.co. When patients know they can easily ask a question and get a response from a nurse or coach through the app, they are more likely to continue using it. These communication features strengthen the patient-provider relationship and make the app a convenient one-stop hub for help. Telehealth integration is an extension of this – for instance, embedding video call functionality so that patients can have remote appointments or check-ins without leaving the app digitalya.co. By integrating such support, apps keep users coming back not just for information, but for human interaction and reassurance, which are crucial in healthcare.

• Incorporating Reminders and Notifications (Intelligently): Virtually all adherence-focused apps have reminder notifications, but the frequency and intelligence of these reminders is key. Overly frequent or generic notifications can lead users to tune out (or uninstall the app), so successful apps often allow customization (user can choose timing, tone) and use context-aware reminders. For example, the app might send a gentle nudge if a dose is missed, or a refill reminder when the medication supply is running low, sometimes synchronized with pharmacy services for one-click refills deloitte.com. Some advanced systems use predictive analytics to detect when a patient might be lapsing (e.g., based on a pattern of delayed log-ins) and then trigger a special encouragement message or offer additional support. The key is striking a balance: keeping the app “sticky” with useful reminders, but not so intrusive that it annoys the user. Multi-channel outreach can also be part of the strategy – if app engagement drops, a patient might get an email or text encouraging them to return, or a call from a support coach, thus creating a safety net to re-engage them.

• Rewards and Incentive Programs: In addition to gamification points, some pharma apps tie into real-world reward programs. For example, patients might earn points for each week of perfect adherence that can be redeemed for discounts, charitable donations (sponsored by the company), or entries into sweepstakes. While pharma companies must navigate regulatory limits on incentives, non-monetary rewards or education-based rewards can be effective. There are also cases where insurers or employers partner so that adherence via an app could yield lower copays or other benefits. The psychology of positive reinforcement suggests that even small rewards or recognition (like an app congratulating the user on a streak) can reinforce continued engagement.

• Integration with Wearables and Devices: Many modern pharma apps increase engagement by integrating with wearable devices or smart medical devices. For example, an app for diabetes might connect with a continuous glucose monitor or a smart insulin pen. This automatic data integration spares the patient from manual entry and provides real-time monitoring feedback – making the app more useful and engaging on a daily basis. The Deloitte case of MySugr and Roche is a prime example: MySugr connects with blood glucose meters and insulin pump data, pulling readings into the app seamlessly deloitte.com deloitte.com. Patients can then see their data in one place and get insights; they can also share these with their healthcare team easily. Likewise, apps for respiratory diseases pair with smart inhaler sensors (e.g., Propeller Health’s platform) to track usage – when the sensor detects a puff, the data goes to the app, which can then coach the patient if doses are missed. This device integration not only provides richer data for the patient and provider, but also tends to lock in the user: if the app is the hub for their device readings, they have reason to open it frequently. Studies show that such integration improves outcomes (e.g., asthma patients using inhaler sensors had higher adherence and fewer exacerbations) digitalya.co digitalya.co. From the pharma perspective, integration yields valuable data and makes their app a central part of daily disease management, increasing engagement time.

• Accessibility and User-Centric Design: A less flashy but crucial engagement strategy is ensuring the app is easy to use and accessible to a wide range of patients. Successful apps invest in user-centered design – simple interfaces, clear language, and features like large text options, text-to-speech, or multilingual support digitalya.co. If an app is cumbersome or excludes certain users (for example, older patients with low tech literacy or those with disabilities), engagement will suffer. Pharma companies have learned that to maintain engagement, apps must accommodate patients’ varying needs. Features like voice controls or screen readers can make an app usable for the visually impaired or those who cannot comfortably use a touchscreen digitalya.co. By being inclusive, pharma apps can reach more users and keep them engaged. A study cited in one industry review emphasized the importance of accessibility, noting that digital health tools must ensure all patients can benefit – otherwise, the ones who might need the most support could be left out revolve.healthcare. Additionally, user feedback loops (like in-app surveys or beta testing with patient groups) are used by successful apps to continuously refine the user experience.

In practice, the best-performing pharma apps use a combination of these strategies. For instance, a top-rated companion app might send personalized reminders (with a friendly tone using the patient’s first name), offer a community forum, award points for each day of adherence, integrate with a fitness tracker to log steps, and allow one-tap access to chat with a nurse. All these features work synergistically to create an engaging ecosystem that encourages regular use. The underlying principle is that engagement drives outcomes: the more a patient interacts with supportive tools, the more likely they are to stay on therapy and achieve positive health results revolve.healthcare revolve.healthcare. Hence, pharma companies are keen on deploying evidence-based engagement techniques – like gamification, personalization, and social support – to maximize the impact of their apps on both patient well-being and brand success.

Metrics for Measuring App Engagement and ROI

To evaluate the success of mobile apps in pharma marketing, companies track a variety of engagement metrics and return-on-investment (ROI) indicators. These metrics help determine whether an app is effectively engaging its users and contributing value to the business or patient outcomes. Key measures include:

• Active User Metrics: Pharma apps closely monitor Monthly Active Users (MAU) and Daily Active Users (DAU) as core indicators of engagement. These metrics represent the number of unique users logging into the app within a month or day, respectively. A growing MAU/DAU suggests the app is gaining adoption and retaining users. Companies often look at the ratio of DAU to MAU (sometimes called “stickiness”) to gauge how frequently users engage; a higher ratio means users are returning regularly rather than just signing up once and lapsing cometchat.com. For example, if an app has 10,000 MAUs and 1,000 DAUs, that means on average 10% of the monthly users engage daily – there may be room to increase daily utility. Weekly Active Users (WAU) is another variant that can be relevant for apps not intended for daily use. Pharma marketers set targets for active user counts based on the patient population and promotion reach of the app. These active user metrics are analogous to how one would track usage of any mobile app, but in pharma they are tied to the therapy’s patient base (e.g., a niche rare-disease app might consider 1,000 MAUs a success if that’s a significant portion of the patient community).

• Retention and Churn Rates: Retention rate is the percentage of users who continue to use the app over a given time period (e.g., 30-day retention, 90-day retention), whereas churn rate is the inverse (the percentage who drop off). This is a critical engagement metric, as it directly reflects how well the app sustains user interest after onboarding. Pharma apps often struggle with retention after initial download – one analysis noted that across proprietary pharma apps for physicians, total downloads remained low, implying many potential users never even got on board or didn’t stick with the app insights.medsynapse.app. For patient apps, retention can be measured by how many users are still active X months after enrollment. If, say, only 20% of users are active after 3 months, that indicates significant drop-off that needs addressing. In healthcare, retention can also be tied to medication persistence. For instance, are patients who keep using the app also the ones who stay on therapy longer? A study by ZS Associates highlighted the overall challenge: pharma companies lose up to 50% of new patients within just 2 months of starting therapy, and 70–80% within 6 months (due to medication non-adherence/discontinuation) zs.com. Improving those stats is a primary ROI of an effective app. Thus, if an app can be shown to meaningfully increase 6-month retention on medication (say from 20% to 30%), that is a huge win both clinically and commercially. Retention metrics for the app itself (continued usage) are often used as a surrogate for this, under the assumption that engaged app users correlate with adherent patients zs.com zs.com. Pharma might also measure retention by feature – e.g., what percentage of users who set up medication reminders are still using that feature after 90 days.

• Session Length and Frequency: Another engagement measure is how long and how often users interact with the app. Average session length indicates the typical time a user spends in the app per visit, and session frequency (or sessions per user per week) indicates how often they come back. For a support app, one might expect shorter but frequent sessions (e.g., checking off a dose might only take 30 seconds, but done twice a day). If an educational section of the app has a longer session length (say users spending 5 minutes reading articles), that suggests deep engagement with content. Monitoring these metrics helps identify which features are most engaging. An uptick in session frequency after adding a new feature could demonstrate its success. Conversely, declining session lengths might indicate users aren’t finding new value and just quickly log tasks. There are industry benchmarks for session length by app category storyly.io, though pharma apps are somewhat unique in purpose. Generally, increasing frequency of use (e.g., daily check-ins) is a goal, as regular use translates to more consistent adherence behaviors.

• Feature Utilization Metrics: Pharma teams track specific in-app actions that correspond to desired behaviors. For example: the number of medication doses logged per user per week, the percentage of users setting up at least one reminder, or the proportion of users who have connected a wearable device. These micro-metrics help assess if the app is being used as intended. If only 30% of users are using the pill reminder feature, is it because it’s not obvious or not useful? Or if a low percentage connects their glucose monitor, perhaps integration needs improvement. For HCP-facing apps, feature metrics could include how many times clinical calculators are used, or how many e-details (digital detail aids) are viewed by a doctor. Each metric ties back to the engagement objective: e.g., if “questions asked to nurse via chat” is high, that shows strong interactive engagement and an opportunity to further support those users. On the other hand, if a critical feature like “refill request through app” is underused, that might signal a UX problem or external barrier.

• Outcomes and Behavior Change Metrics: Beyond usage, pharma is very interested in whether the app drives real-world behavior changes and improved outcomes. These are the ultimate ROI metrics. Some examples:

• Adherence rate: The primary outcome for many apps is medication adherence, often measured as proportion of days covered (PDC) or a similar metric. Through the app’s data or linked pharmacy data, pharma can calculate if app users have higher adherence than non-users. For instance, do patients using the app take 90% of doses on time vs. 70% for those not using it? Any significant uplift can be attributed to the app’s interventions. McKinsey reported that with data-driven adherence programs (not necessarily all app-based), leading companies have improved adherence by 10–15% in targeted patient segments mckinsey.com. That level of improvement is substantial in chronic disease management and would be a key success indicator for an app.

• Persistence (therapy duration): How long do patients stay on therapy before discontinuing? If an app can extend persistence (e.g., the average patient stays on drug 8 months instead of 6), that is both a health win and a sales win. Persistence can be measured via prescription refill data or patient self-report in the app.

• Clinical outcomes: Some apps capture health outcomes directly – for example, an asthma app might track lung function or number of asthma attacks; a diabetes app might track blood glucose or HbA1c levels. Improvements in these metrics among engaged users are a powerful demonstration of value. In retrospective studies, the MySugr app users showed improved HbA1c and reduced risk of severe diabetes events, validating the app’s clinical benefit deloitte.com.

• Engagement outcome proxies: For instance, reduction in self-reported symptoms or improvements in a patient’s quality-of-life scores over time in the app.

• Healthcare utilization: As an ROI measure for payers/providers, did app users have fewer hospitalizations or ER visits? Some pharma app programs aim to show pharmaco-economic benefits. One UK-based app (the myGP app) reported that widespread use among 2.4 million patients helped unburden the healthcare system by reducing unnecessary appointments digitalya.co. Such metrics can be cited to justify the app’s existence and support from healthcare systems.

• ROI and Business Metrics: Pharma also evaluates the direct and indirect ROI. Indirect ROI includes the medication adherence gains discussed (which lead to higher medication sales volume). If a companion app is shown to increase adherence, the company can estimate the additional prescriptions or refills that result – for example, a 5% increase in adherence in a population of 10,000 patients might equate to hundreds of additional prescription fills, which is significant revenue given the cost of many drugs. Deloitte noted that companion solutions can drive an increase in medication sales by 3–20% by finding more patients, getting earlier diagnosis, and improving adherence deloitte.com. On the direct ROI side, while most pharma apps are free and not intended to generate revenue, some apps that double as digital therapeutics might be reimbursed. In such cases, metrics like number of prescriptions or subscriptions for the app, and revenue from those, would be tracked. However, common practice is to offer apps at no charge to support the core product deloitte.com. Instead, pharma may look at ROI in terms of cost avoidance (did the app reduce need for call center support or paper educational materials?) and brand value (improved Net Promoter Score from patients or better formulary positioning due to the support program).

• User Satisfaction and Feedback: Metrics like App Store ratings, net promoter score (NPS) surveys, and direct feedback are also crucial. A high app rating (e.g., 4+ stars) and positive reviews signal good user engagement and satisfaction. Pharma companies often collect qualitative feedback through the app (e.g., periodic in-app surveys like “How helpful do you find this app?”). High satisfaction correlates with continued use and willingness to recommend the app to others (including HCPs recommending it to patients). User feedback also guides iterative improvements, which can then be measured by improved engagement stats after updates.

In summary, measuring engagement and ROI for pharma apps is a multidimensional effort. Companies track usage metrics (active users, frequency, session time), behavior metrics (adherence, persistence, outcomes), and satisfaction metrics (feedback scores). Success is typically defined by a combination of sustained user engagement and demonstrable improvements in patient behavior or outcomes. An app that has thousands of active users but no impact on adherence would not meet the ultimate goal, just as an app that could theoretically improve adherence but fails to keep users active would fall short. The most convincing case for an app’s value is when engagement metrics (e.g., high retention) translate into better health metrics (higher adherence rates) and thereby deliver a return in the form of healthier patients and increased therapy success mckinsey.com deloitte.com.

Challenges and Barriers to App Engagement in Pharma

Despite the promise of mobile apps, pharmaceutical companies face significant challenges and barriers in achieving strong engagement and widespread adoption. Some of the key hurdles include:

• Regulatory and Compliance Constraints: Pharma operates in a highly regulated environment, and this extends to digital tools. Apps intended to support a medication must be careful not to stray into promotional claims beyond the drug’s approved label, and they must report adverse events if mentioned by users. In some jurisdictions, if an app provides specific health guidance, it may be deemed a medical device requiring regulatory approval. This means lengthy development and approval cycles that are at odds with the fast pace of software iteration. Regulatory concerns can make pharma companies overly cautious in app design (e.g., including too many disclaimers or limiting functionality), which can hurt user experience. Moreover, compliance with healthcare regulations like HIPAA (in the U.S.) and GDPR (in Europe) around patient data privacy is non-negotiable digitalya.co. Ensuring all data is encrypted, securely stored, and used with proper consent adds complexity and cost. These necessary safeguards might slow down development and sometimes limit features (for example, sharing data with HCPs requires consent flows and secure transfer mechanisms). Navigating global regulatory differences is also challenging – what’s allowed in one country might not be in another, forcing companies to either maintain different app versions or limit functionality to the strictest common denominator. In summary, regulation is a double-edged sword: it protects patients but also poses hurdles to rapid innovation and can stifle some engagement features (for instance, pharma must be careful with gamification rewards to avoid being seen as inducing drug use inappropriately).

• Data Privacy and Security Concerns: Patients may be wary of using pharma apps due to privacy concerns – not wanting a drug company to have their personal health data. Pharma companies must work hard to build trust that user data will be protected and not misused. Any data breach or misuse could be extremely damaging. Thus, robust security measures (encryption, secure authentication, routine security audits) are essential digitalya.co digitalya.co. However, implementing top-notch security can sometimes make apps less convenient (e.g., requiring two-factor login each time, which might deter some users). Ensuring privacy also means being transparent about data use. Pharma companies often include detailed privacy policies and user consent forms, but these can intimidate users during onboarding, causing drop-off. Additionally, restrictions on data use can limit some engagement opportunities – for example, an app could theoretically personalize content based on a patient’s exact profile, but privacy rules might limit usage of certain sensitive data without explicit consent. Another aspect is ownership of data: if a patient wants to share their app data with their doctor, systems must be interoperable and secure. Any friction here can become a barrier to the app’s perceived usefulness. In essence, while privacy and security are mandatory, managing them gracefully so as not to impede user experience is a delicate challenge.

• Low Initial Adoption & Onboarding Issues: One of the biggest practical barriers is simply getting patients to download and consistently use the app. Many pharma-launched apps historically have suffered from low awareness and uptake. Physicians might not always remember (or have time) to recommend the app to patients, and patients often do not seek out an app unless prompted. Even when they do download, the onboarding experience is critical. If the registration process is too long or the app doesn’t quickly demonstrate value, users may abandon it. The reality is that people have app fatigue – convincing a patient to use yet another app daily is hard unless it clearly makes their life easier. In fact, a commentary on digital health adoption noted that many chronic disease apps struggle because patients feel managing their disease is burdensome and prefer if someone else (like a clinician or insurer) handles it telecareaware.com telecareaware.com. There’s also a sentiment that if an app is important, insurance or healthcare providers should provide it – many patients are reluctant to pay for apps or invest time without external encouragement telecareaware.com. This ties into the barrier of cost and reimbursement: while pharma usually provides apps free, the lack of formal prescription or integration into care pathways can make patients view them as optional or non-essential.

• Sustaining Long-Term Engagement (Motivation): Even if initial adoption is achieved, maintaining engagement over the long term is challenging. Human behavior is hard to change – many patients start with good intentions but revert to old habits. Using an app to track meds may drop off as the novelty wears off. A cited HBR piece observed that managing chronic disease is something most people prefer to “avoid” thinking about, which is why many standalone adherence apps struggle without continuous reinforcement or outside incentives telecareaware.com. Keeping content fresh and relevant over months and years requires continuous updates and sometimes integration with the patient’s evolving care (like new treatment phases, or adding new goals). Pharma companies historically launch apps as projects but may not allocate resources for ongoing content and feature enhancements, which can lead to apps becoming stale. Additionally, if an app is tied to a single medication, once the patient’s treatment is changed or stopped, the app may lose all relevance. Ensuring interoperability or multi-condition support can mitigate this, but not all pharma are willing to make their app useful beyond their product due to competitive reasons.

• Integration into Clinical Workflow: On the HCP side, a major barrier is integrating app use into routine clinical practice. Doctors and nurses already have limited time and many systems (EHRs, patient portals) to manage. Expecting them to adopt a pharma app dashboard or to monitor data coming from an app can be a hard sell unless it clearly saves them time or improves outcomes. If an app sends alerts or reports to HCPs, it might be ignored if not well integrated into the physician’s existing tools. Lack of integration with EHRs is often cited – if the data from a patient app doesn’t flow into the medical record or usual systems, it requires extra effort from providers to look at a separate interface, which may not happen. This can become a barrier to physician buy-in. Without physician encouragement or review of data, patients may also lose motivation to use the app (“if my doctor isn’t looking at it, why bother logging all this?”). Some healthcare professionals are also skeptical of pharma-sponsored apps, worrying they might contain bias or promotional material. Overcoming these perceptions and demonstrating clinical value to providers is an ongoing challenge.

• Content Quality and Clinical Validation: To truly engage users, apps must provide credible and useful content. Pharma must ensure that educational materials are up-to-date and evidence-based. However, getting content medically reviewed and approved (often through internal regulatory reviewers) can be slow, resulting in less agility. If patients find generic or overly cautious content that doesn’t tell them anything new, they may not return. Similarly, if an app has a feature like a symptom checker or dosing calculator, it needs to be accurate and preferably validated by studies. Achieving clinical validation (proving the app’s effect in studies) is a barrier that many apps have yet to overcome. Without published evidence, some users (and definitely many clinicians) might not trust the app’s recommendations fully. Generating such evidence requires investment in trials or studies, which not all companies are willing to do for a free companion app. This creates a bit of a Catch-22: evidence could drive adoption, but limited adoption makes it hard to collect evidence.

• Competition and Digital Overload: Ironically, another barrier is the abundance of health apps available. With hundreds of thousands of health apps out there drugstorenews.com, patients and doctors have to choose where to focus. Many patients already use popular general apps (like general pill reminder apps, fitness trackers, etc.). Convincing them to switch to or add a pharma-specific app can be tough unless it offers clear advantages. For example, a patient might say, “I already use MyFitnessPal to track everything, why use this separate app for my drug?” The fragmentation of apps can lead to “app fatigue.” Some pharma are responding by partnering or integrating with existing popular platforms instead of building from scratch. But when going alone, they face a crowded marketplace for attention.

• Resource and Maintenance Challenges: From the pharma company’s perspective, building and maintaining apps requires capabilities that are not traditionally core in pharma (software development, user experience design, data analytics on user behavior). Some early attempts by pharma resulted in clunky apps because of this inexperience. Now, as mentioned, partnerships help, but it’s still a challenge to keep an app updated (compatibility with new phone OS versions, incorporating user feedback, adding features to stay relevant). The cost of ongoing maintenance can be significant, and if an app doesn’t show quick success, there may be internal pressure to abandon it. The digital health funding rollercoaster (as of early 2023, funding had cooled compared to the digital health boom) also means some external partners might go out of business (indeed, several digital therapeutics startups did shutter or pivot) drugstorenews.com drugstorenews.com, leaving pharma in a lurch if they were dependent on those. Ensuring sustained internal commitment to a digital program is sometimes difficult in large pharma companies that are organized around drug development and sales more than long-term software endeavors.

In summary, while pharma apps hold great potential, they operate amidst numerous barriers: stringent regulatory requirements, the need to protect privacy (and thus sometimes limiting functionality), difficulty in getting patients and providers to adopt yet another tool, and the challenge of maintaining engagement over time. Many apps have seen low utilization because they were not sufficiently integrated into care or because patients expected someone else to encourage their use. There’s also an inherent complexity in aligning an app’s benefits with stakeholder incentives – e.g., patients want improved health, providers want efficient care, payers want cost savings, pharma wants loyalty and sales – the app has to deliver at least a bit for everyone to truly succeed. The Harvard Business Review authors summed it up by saying successful chronic disease apps require finding someone (an employer, health system, etc.) who actively drives adoption and diffusion – it’s not a “build it and they will come” situation telecareaware.com telecareaware.com. Pharma companies are learning from these past lessons and are trying to address barriers (for instance, by working with payers to possibly get apps reimbursed or integrating with provider systems), but challenges remain significant.

Regulatory and Compliance Considerations

When deploying mobile apps in the pharma industry, regulatory and compliance factors are paramount. Apps that relate to prescription drugs must navigate a web of healthcare regulations to ensure patient safety and data protection, and to remain within legal promotional boundaries. Key considerations include:

• FDA Guidance (PDURS) in the United States: The U.S. Food and Drug Administration has issued a draft guidance on Prescription Drug-Use-Related Software (PDURS), which directly addresses pharma companion apps. This guidance essentially divides such software into two categories geneticdigital.co.uk:

• FDA-required labeling: If an app’s function is deemed necessary to fulfill the drug’s approved use (for example, a dosing calculator that is essential for a safe use of the drug, or an app that has demonstrated clinical benefit as part of therapy), then the output of the software may be considered part of the drug’s labeling. Such apps likely require FDA review and approval because they can impact clinical outcomes.

• Promotional labeling: Apps that are more about patient engagement, education, or support without altering the drug’s effects are treated as promotional materials. They must still comply with FDA advertising/promo regulations (e.g., present balanced information, include necessary safety info if any drug-specific info is given) but are not subject to pre-market approval as a device. For instance, an app that reminds you to take your pill and provides disease info might be considered promotional labeling associated with the drug.

Pharma companies must determine where their app lies on this spectrum. If it crosses into the territory of making treatment recommendations or influencing dosing beyond the label, it could be regulated as a medical device software. In fact, some companion apps that provide dosing guidance or diagnostic support have sought FDA clearance as Class II medical devices (like insulin dose calculators). The FDA’s current approach is risk-based – many simple reminder or tracker apps are low-risk and don’t require FDA approval, but anything providing clinical decision support might. Compliance with PDURS means that if an app is linked to a drug, the company should submit it to FDA for review if it performs functions that could affect use of the drug. Even for promotional apps, companies often voluntarily submit them to FDA’s OPDP (Office of Prescription Drug Promotion) for advisory review to ensure all claims are on-label and fair balanced.

• EU and UK Medical Device Regulations: In Europe, pharma apps may fall under the EU Medical Device Regulation (MDR) or, post-Brexit, the UK’s MHRA rules. If an app performs a medical purpose (diagnosis, prevention, treatment, monitoring of disease) and works on data, it can be classified as a medical device. Not all pharma apps are medical devices – if they’re purely educational or a simple diary, they may not meet the definition. But if an app analyzes patient data to make recommendations, it likely is. For example, the MySugr app’s bolus (insulin) calculator is classified as a Class IIb medical device in the EU deloitte.com. Under MDR, manufacturers of such apps need to go through conformity assessment (often involving a Notified Body) to obtain CE marking for Europe. The UK has introduced the UKCA mark as an equivalent for the British market geneticdigital.co.uk. Compliance steps include:

• Determining the risk class of the software (Class I, IIa, IIb, III) based on impact. Many companion apps might be Class I (low risk) if they don’t provide actionable medical recommendations, but any that do analytics for treatment decisions could be Class II or higher.

• Preparing technical documentation, demonstrating safety, clinical performance (which could require clinical data), and meeting general safety and performance requirements.

• Undergoing audit/certification for higher classes.

Pharma companies thus need regulatory expertise in software – sometimes a new competency – or partner with digital health companies that have it. An example of meeting these regulatory standards: MySugr obtained CE marking and is registered under EU regulations, which required demonstrating its app’s accuracy and data security deloitte.com. The regulatory burden can be heavy; however, regulatory approval can be a differentiator, as it signals to users and HCPs that the app meets high standards (indeed, some health apps now appear in regulatory agency databases of approved devices).

• Digital Technology Assessment Criteria (DTAC) in the UK: The NHS in the UK has a Digital Technology Assessment Criteria for health apps and tools geneticdigital.co.uk. Pharma companies aiming to have their apps used in the NHS context need to meet DTAC standards which cover:

• Clinical Safety: showing that the app does not pose harm – typically a clinical risk management plan is required.

• Data Protection: compliance with GDPR and UK data laws, ensuring patient data is handled lawfully and transparently.

• Technical Security: meeting cybersecurity best practices, encryption, etc.

• Usability and Accessibility: demonstrating the app is accessible to users with disabilities, and has been user tested for good usability.

• Interoperability: if relevant, that the app can integrate with NHS systems or data standards (like using FHIR protocols for data exchange).

These criteria essentially serve as a quality kitemark. An app that passes DTAC is more likely to be trusted by clinicians and potentially commissioned by NHS entities. Pharma companies thus often conduct rigorous assessments or hire third-party evaluators to ensure DTAC compliance when targeting the UK market geneticdigital.co.uk.

• HIPAA and Health Data Privacy: In the United States, if the app is sponsored by a pharma company and involves personal health information being shared with healthcare providers or insurers (i.e., with “covered entities”), HIPAA laws may kick in. Even if the pharma itself isn’t a covered entity, they often design apps to HIPAA standards as a best practice because apps may share data with doctors or via cloud services that handle PHI. HIPAA requires safeguards for privacy and security, and gives patients rights over their data. Additionally, many pharma apps voluntarily align with standards like HITRUST or others to assure users of privacy. One complexity is adverse event reporting: if a patient mentions a side effect in an app forum or chat, the company has regulatory obligations to report that. So they must design the app moderation and data handling to capture such information for compliance, while still respecting privacy (usually spelled out in terms that if you report an AE, it may be shared with regulators, etc.). GDPR in Europe is even more stringent in some ways – users have rights to access and delete their data, and pharma must have a lawful basis to process health data (typically explicit consent). Designing the app to allow data deletion on user request, and to minimize data collection (data minimization principle), is important under GDPR digitalya.co.

• Promotional Compliance and Ethical Considerations: Pharma apps must comply with laws governing drug promotion, such as avoiding off-label promotion. If an app provides educational info, it must be consistent with the drug’s approved use unless it’s “unbranded” disease education. Many pharma choose to make companion apps unbranded (not explicitly named after the drug) to focus on disease management broadly, which provides more leeway in content and might feel more neutral to patients/HCPs. However, even unbranded apps, if funded by pharma, often include disclaimers and adhere to industry ethical codes (like not disparaging competitors or not providing inappropriate inducements). In Europe, pharma must be careful about anything that could be construed as direct-to-consumer promotion of a prescription drug (since DTC advertising is not allowed in most countries there). A companion app might get away with it if it’s solely for patients already prescribed the medication (i.e., it’s a support program, not an advertisement), but the content has to be informational, not marketing. Similarly, for HCP apps, any promotional content should include the necessary prescribing information and not preempt regulatory approval for new indications, etc.

• Intellectual Property and Content Permissions: While not a regulatory law per se, pharma apps need to ensure they have rights to any content (images, questionnaires, algorithms) they use. For example, if an app uses a depression scale or a quality-of-life questionnaire, those often are copyrighted and require licenses. Overlooking this can lead to legal issues.

• Post-Market Surveillance: Especially if the app is considered a medical device, regulators expect ongoing monitoring of performance and any incidents. Even outside formal device classification, pharma companies will monitor for any bugs or issues that could affect patient safety, and they typically have a pharmacovigilance plan that extends to the app (e.g., how to handle if the app gives an incorrect recommendation). For apps under MDR, a post-market surveillance plan and periodic safety update reports are required. This means companies must have infrastructure to collect user feedback and incident reports, and to update the app to fix any issues – a change management process that may sometimes need regulatory notification or approval for significant changes.

In essence, regulatory compliance is a foundational aspect of pharma app development. It can be seen as a challenge (as described in the previous section) because it adds layers of complexity, but it’s fundamentally about ensuring patient safety and trust. When done correctly, compliance can even be a selling point: a pharma app that is certified and meets high standards can distinguish itself from the thousands of unregulated health apps. For example, a note from Deloitte’s analysis highlights that MySugr’s Logbook is classified as a Class IIa medical device in the EU and complies with those regulations deloitte.com, giving users and providers confidence in its accuracy and reliability. Pharma companies must work closely with legal, regulatory affairs, and compliance teams at every step of the app’s life cycle – from design (privacy by design, safety by design) to deployment (appropriate disclaimers, app store descriptions that are compliant) and maintenance (handling updates under change control).

One emerging regulatory development is the concept of prescribing apps formally (as in Germany’s DiGA). If an app is to be prescribed, it usually needs to meet extra regulatory scrutiny and demonstrate evidence of benefit. In Germany, for instance, DiGA-approved apps have to show positive healthcare effects (either medical outcomes or process improvements) and comply with strict data protection, information security, quality, and consumer protection requirements. Pharma companies eyeing such pathways have to effectively treat the app as part of the therapeutic intervention on par with a device or drug in terms of evidence and oversight.

Finally, compliance with industry codes (like those from PhRMA in the US or EFPIA in Europe) is important. If the app involves any kind of patient support that has financial value (like co-pay assistance via the app, or giveaways), those need to be structured to comply with anti-kickback statutes and pharma marketing codes. Similarly, if the app collects data that the pharma wants to use for research, appropriate consent and perhaps Institutional Review Board (IRB) oversight could be needed.

In conclusion, regulatory and compliance considerations permeate the entire design and operation of pharma mobile apps. While complex, they ensure that these digital tools uphold the same standards of safety, efficacy, and ethical marketing that apply to pharmaceuticals themselves. Companies that effectively manage these considerations can safely leverage apps to improve patient care within the boundaries of the law pmlive.com geneticdigital.co.uk.

Case Studies of High-Performing Pharma Apps

Examining real-world examples provides insight into what success looks like in pharma app engagement. Below are several case studies of high-performing apps, spanning both patient-facing and HCP-facing solutions:

1. MySugr (Diabetes Management App by Roche): MySugr is often cited as a flagship success in the pharma app arena. Originally a startup product, MySugr was acquired by Roche in 2017 and became a core part of Roche’s diabetes care ecosystem deloitte.com deloitte.com. The app serves as a companion for patients with diabetes, offering an electronic logbook for tracking blood sugar readings, insulin doses, carbohydrate intake, physical activity, and other metrics. It connects seamlessly with various devices – glucometers, insulin pumps, continuous glucose monitors, even smart insulin pens (notably integrating with Novo Nordisk’s connected insulin pen) deloitte.com. This integration allows automatic data capture, which is hugely convenient for users. Engagement strategies in MySugr include gamification (users earn points for entries, with a playful monster theme as the app’s mascot to “tame” by good control) digitalya.co, personalized feedback on blood sugar trends, and motivational messages. The app also provides rewards for regular logging and has challenges users can participate in. A key to MySugr’s success is its tangible impact: retrospective studies demonstrated improved glycemic control (lower HbA1c) among users and reduced risk of diabetes-related complications deloitte.com. By keeping patients engaged in daily self-monitoring, MySugr helps drive behavior change. From a metrics standpoint, MySugr boasts over 4 million registered users across 80+ countries deloitte.com – a huge user base for a disease-specific app. It holds medical device status in the EU (class IIa for the logbook, IIb for the bolus calculator), underscoring its clinical robustness deloitte.com. Roche leveraged MySugr as more than just an app: it’s the digital front-end for their suite of diabetes services, and patients can even share their data directly with providers through platforms like Roche’s Diabetes Care Platform deloitte.com. Key takeaway: MySugr’s success came from excellent user-centric design, integration with treatment tools (making it very useful), and evidence of real outcomes. For Roche, it has enhanced brand loyalty – Roche’s diabetes products (like Accu-Chek devices) now have additional value by linking with MySugr, fostering customer stickiness.

2. Re-Mission (Gamified App for Pediatric Cancer by HopeLab): Re-Mission is a unique case – developed by a nonprofit (HopeLab) with support from healthcare companies – but it often serves as a case study for gamification in health. It’s a video game (originally a PC game, later a mobile app version called Re-Mission 2) designed for adolescents with cancer. Players control a microscopic robot that shoots cancer cells and manages side effects in animated scenarios. The psychological premise is that by symbolically fighting cancer in the game, young patients feel more empowered and adherent in real life. Clinical studies on Re-Mission showed that patients who played the game had higher adherence to antibiotics and chemotherapy and better cancer-related knowledge than those who didn’t digitalya.co. The game improved motivation and sense of control, which translated to adherence behavior (e.g., maintaining chemotherapy schedules). This case illustrates how engaging content tailored to the patient’s context (in this case, a game for teens) can improve outcomes. Pharmaceutical companies often reference Re-Mission as proof that creative digital interventions can tangibly impact adherence. While not a commercial pharma app, its success has inspired pharma to incorporate gamified elements and to pay attention to the fun factor in patient engagement.

3. Propeller Health (Respiratory Disease App and Sensor, partnered with multiple pharma): Propeller Health is a digital health company (now part of ResMed) that created a platform for asthma and COPD management. It includes a small sensor that attaches to inhalers and a smartphone app. The app automatically tracks inhaler use via Bluetooth and provides insights (like identifying triggers, tracking usage patterns) and sends medication reminders if doses are missed. Propeller partnered with pharma companies such as GlaxoSmithKline and Boehringer Ingelheim to distribute sensors for their inhalers and integrate the solution into patient support programs. In clinical studies and real-world deployments, Propeller achieved impressive results: asthma medication adherence improved and patients experienced fewer exacerbations. One study found significant increases in daily controller medication use and a reduction in rescue inhaler use when using Propeller’s system, indicating better asthma control (these improvements can be on the order of 15-20% increase in adherence, depending on population). Propeller’s app keeps users engaged by providing immediate feedback – for example, it alerts users when it detects increased rescue inhaler use (possible sign of worsening asthma) and prompts them or their physician for action. It also gives a monthly report that patients can share with their doctor. This creates a feedback loop that reinforces usage. Pharma’s interest in Propeller was that it could be tied to their specific inhaler products, potentially improving outcomes (and thus differentiating their inhaler in a commoditized market). For instance, BI offered Propeller sensors for its Spiriva Respimat inhalers in a program to enhance adherence. The Propeller case study shows the power of device-app integration and partnering: rather than build their own from scratch, pharma leveraged an existing best-in-class platform. It stands as a high-performing example with FDA-cleared technology and peer-reviewed evidence.

4. Novartis – ViaOpta and FocalView (Niche apps for specialty areas): Novartis has experimented with various apps. ViaOpta apps are a suite of tools Novartis developed for visually impaired patients (related to its ophthalmology franchise). ViaOpta offers features like object recognition (using the phone camera to speak what’s in front), voice-guided navigation, and a magnifying glass – essentially helping low-vision patients in daily tasks. While not directly about a drug, it was a value-add targeting patients who might be using Novartis eye treatments. It was well-received in the low-vision community as a philanthropic and brand-building effort. Another interesting app by Novartis was FocalView, an app for conducting vision tests on iPhone, intended to facilitate ophthalmology clinical studies remotely. This was more R&D-focused, but it illustrated regulatory acceptance: it sought to collect patient-reported vision data for trials and had to ensure accuracy. These apps show pharma engaging beyond medication to support patients’ broader needs, building good will and engagement even if they don’t directly drive medication adherence. Success here is measured in user adoption and positive sentiment. For example, ViaOpta won industry awards for innovation in 2015–2016 and demonstrated how offering genuinely useful tools (like recognizing currency for someone who can’t see well) can enhance company reputation.

5. Otsuka and Proteus – Abilify MyCite (Digital Pill System): One of the more novel pharma app integrations was Otsuka’s Abilify MyCite, the first FDA-approved digital pill. It combined the antipsychotic pill (aripiprazole) with an ingestible sensor by Proteus Digital Health that communicates to a patch and then to a smartphone app to track ingestion. The system aimed to address adherence in patients with serious mental illness. The MyCite app allowed patients (and with consent, their caregivers and doctors) to see if/when the medication was taken, along with patient-reported mood and rest. While technologically groundbreaking (approved by FDA in 2017), in practice it faced challenges. Some patients found it useful to have confirmation of taking medication, but others felt it intrusive or burdensome to wear the patch. The uptake was limited and Proteus (the tech partner) eventually went bankrupt in 2020, showing the difficulty of commercializing such complex solutions. However, it’s a case study in regulatory and technical integration: the FDA treated the pill+app as a combined product with labeling about the tracking function. It highlighted ethical considerations too (informed consent, privacy of adherence data). Engagement-wise, the app had to engage not just patients but also doctors to check the dashboard. The project’s mixed results underscore that even high-tech solutions need to align with user preferences and trust. Otsuka continues to explore digital adherence tools, but MyCite’s story is often analyzed to learn about user acceptance and the importance of ensuring the digital experience truly adds value for the patient population in question.

6. HCP-Facing Apps and Portals (Various Companies): On the healthcare provider side, several pharma companies have launched apps or portals aimed at doctors and other professionals:

• For instance, Merck’s Manual App (MSD Manual) is a digital version of the famous Merck Manual medical reference. It’s free and widely used by HCPs and students as a clinical reference guide. While it’s educational rather than promotional, it certainly keeps Merck’s name in front of providers in a helpful way, subtly aiding brand image.

• PfizerPro is Pfizer’s online portal for HCPs which is mobile-optimized (and in some regions has an app). It provides product information, clinical resources, patient materials, and allows online sample requests. The success of such portals can be seen in usage stats like number of registered HCP users and engagement time. Pfizer has reported increased digital engagement from HCPs as they enhanced these platforms (for example, during COVID, reps had to rely on digital, and PfizerPro usage grew as a result).

• One global pharma (case anonymized, but referenced via Indegene) implemented a unified HCP app platform that led to 200× increase in traffic and over 100,000 downloads indegene.com. This suggests that when done well – likely by providing valuable content and a good user experience – even busy physicians will use pharma apps. Features that drive HCP app engagement include: medical calculators, dosage converters, continuing education modules, and conference scheduling tools. Some pharma event apps (for medical conferences or sponsored events) have also seen high uptake, especially in the era of virtual/hybrid events.

For HCP apps, a critical measure of success is whether they help drive meaningful interactions or practice improvements. For example, an HCP app might track how often guidelines or formulary information is accessed and correlate that with prescribing patterns. If providing a diagnostic calculator in an app leads to more appropriate use of a therapy, that’s a win for both patient care and the company’s product use. That said, it’s known that many pharma-created HCP apps struggled to get adoption in the past, partly because doctors already have go-to resources (like Medscape, Epocrates, etc.). The trend now is pharma partnering to provide content within those existing popular apps or focusing on very niche needs not addressed elsewhere (like an app specifically for managing patients on a certain therapy with complex monitoring requirements).

7. Medisafe (Third-Party Adherence App with Pharma Partnerships): Medisafe is not tied to one pharma but worth mentioning as a case study in engagement. Medisafe is a top-rated general medication management app boasting over 7 million users medisafe.com. It allows users to input all their medications, get reminders, and track their progress. Medisafe has partnered with pharma companies to create tailored experiences for specific drugs (for example, onboarding modules or additional content for users on a particular medication). Pharma sees value in leveraging a platform that patients have already adopted. Medisafe’s success factors include a very user-friendly interface, the ability to handle complex regimens, and providing timely reminders and alerts (even alerting a designated family member if a dose is missed, if the user opts in). The app’s high retention relative to many others (internal data from Medisafe claims above-average 30-day retention for health apps) showcases that a well-designed app that simplifies a universal task (remembering pills) can maintain engagement. Pharma partnerships with Medisafe are a way to piggyback on that engagement – for example, if a patient indicates they’re on Drug X, the app might show them specific tips or resources from the manufacturer of Drug X. This can improve adherence specifically for that drug. A case study outcome: In one partnership, a pharma company found that patients using Medisafe for its medication had better adherence (measured via refill rates) than a control group, highlighting ROI in terms of prescriptions filled (exact figures are proprietary, but anecdotal reports suggest double-digit percentage adherence improvements for those engaged with these tools) digitalya.co.

These case studies illustrate several overarching themes:

• Integration and ease of use drive engagement: MySugr and Propeller both integrate with devices to reduce user burden. The more an app fits seamlessly into existing behaviors (like taking an inhaler or checking glucose), the more likely patients are to stick with it.

• Gamification and psychology matter: Re-Mission and MySugr use fun and game elements to make serious tasks more enjoyable. This improves motivation, especially for younger users.

• Evidence of efficacy is key for scaling: The apps that have become widely adopted (MySugr, Propeller, Medisafe) have shown in studies or real-world data that they actually improve metrics like adherence or health outcomes. This not only helps in convincing patients and providers to try them, but also may attract payer support or endorsements from professional organizations.

• Challenges are still present: Even among these successes, we see hurdles – Abilify MyCite was innovative but faced patient acceptance issues; HCP apps need to find the right value proposition to compete with independent medical apps; and sustaining funding (Proteus bankruptcy) or user engagement over years is an ongoing effort.

• Pharma’s evolving role: Initially, pharma tried building many apps on their own and found limited success. Now we see more partnering (with startups like Propeller, Medisafe) and acquisitions (Roche buying MySugr) – essentially incorporating digital expertise. The case studies also show pharma sometimes acting as a digital therapeutic provider (Otsuka with MyCite, Pear Therapeutics partnerships with Sandoz for reSET, etc.), which blurs the line between drug and software.

Finally, an emerging type of case study is digital therapeutics in chronic conditions: for example, Pear Therapeutics (with Novartis) launched reSET-O, an FDA-authorized app for opioid use disorder therapy adjunct. It delivered behavioral therapy via app and was shown in trials to improve abstinence rates. While Pear struggled as a business, the clinical outcomes were positive, and other companies are now carrying that torch. We might soon cite case studies like a successful hypertension management app that, when prescribed alongside meds, significantly improves blood pressure control across a population.

In conclusion, the success stories in pharma apps, whether patient- or HCP-focused, underscore that when an app is useful, user-friendly, and supported by evidence, it can achieve strong engagement and deliver real health and business benefits. These examples serve as valuable lessons for future digital initiatives in pharma.

Future Outlook and Innovations

Looking ahead, the intersection of mobile technology and pharmaceutical marketing is poised to evolve rapidly. Several innovations and trends suggest how app engagement in pharma could further expand and improve in the future:

• AI-Driven Personalization and Coaching: Artificial intelligence is expected to play a growing role in pharma apps. Future apps will likely leverage AI algorithms to analyze user data and behavior in real time, enabling hyper-personalized support. This could mean AI chatbots that converse with patients to answer questions about their condition or medication, providing instant, accurate responses sourced from a vast medical knowledge base. We already see early signs of this: some apps have symptom checker chatbots (like Ada, which Pfizer partnered with for a COVID-19 app deloitte.com) or AI-based health coaches. As AI improves, these virtual assistants will become more adept at mimicking empathic human interaction – checking in with patients regularly, offering encouragement on tough days, and adjusting recommendations based on subtle patterns (for instance, detecting from a user’s inputs that they may be getting depressed and alerting a healthcare provider or suggesting coping resources). Predictive analytics might allow apps to foresee when a patient is at risk of lapsing in adherence or having an adverse event. For example, an AI could learn that a particular patient tends to skip doses when their work schedule is busy or during travel; knowing this, the app might proactively send reminders or deploy tele-coach interventions during those times. This “anticipatory” engagement could dramatically improve outcomes by addressing issues before they fully manifest. Pharma companies are investing in AI capabilities – either in-house or via collaborations – to differentiate their digital offerings. Medisafe, for instance, has discussed AI solutions that tailor patient engagement based on individual patterns, calling it “intelligent patient engagement” medisafe.com. In the future, it’s conceivable that an app might even integrate with voice assistants (like Alexa or Siri) to engage patients through conversation, or use AI for image recognition (e.g., scanning a pill to confirm identity). The overall trend is making apps more interactive, responsive, and “smart,” which should boost engagement because the app experience will be more like a personalized health companion than a static tool.

• Greater Integration with Wearables and IoT: The proliferation of wearables (smartwatches, fitness bands, smart patches) and Internet of Things health devices (smart glucometers, blood pressure cuffs, etc.) provides an opportunity for pharma apps to become central aggregation hubs for health data. In the future, a patient’s pharma app might automatically pull data from their Apple Watch on heart rate and activity, from their smart pill bottle on whether it was opened, and from a connected weight scale – collating a holistic view of the patient’s health. This not only saves manual input (a barrier to engagement) but allows more dynamic features. For example, if a patient’s wearable indicates they haven’t been sleeping well for a few days, the app for their depression medication might prompt them with sleep hygiene tips or notify their care team. Integration with next-generation sensors is also on the horizon: think of ingestible sensors beyond Proteus, or implantable glucose sensors, or even ambient sensors in the home. As healthcare moves towards remote monitoring and telehealth, pharma apps could serve as the patient-facing interface of that ecosystem. This would strengthen their value proposition: the app isn’t just about the medication, it’s the control center for managing the condition. It can be expected that pharma will increasingly partner with device manufacturers (like how Lilly is working with Dexcom for diabetes data, or multiple pharma collaborating on “smart inhalers”) to ensure their therapies come with a rich data stream. For engagement, seeing one’s own real-time data is powerful – it can motivate patients when they see improvements, or alert them when things are off track, prompting timely action.

• Digital Therapeutics and Combination Products: The line between drug and software will continue to blur. We anticipate more “digital therapeutic” apps that are prescribed alongside drugs or even instead of drugs for certain conditions. These are software programs that have demonstrated clinical efficacy (often through rigorous trials) and can obtain regulatory approval and reimbursement. Pharma companies are increasingly investing in this space, sometimes developing companion apps that have therapeutic claims themselves. For example, in mental health or neurology, an app might deliver cognitive behavioral therapy techniques or neurological exercises that complement pharmacotherapy. The future might see combo offerings where the FDA approves a drug-app pair as a therapeutic package (akin to what Abilify MyCite attempted). With many countries’ regulators formalizing approval pathways for digital therapeutics (the FDA has several, Germany’s DiGA is actively approving many, etc.), pharma-marketed apps could become standard components of treatment guidelines. Imagine if, for diabetes, along with Metformin a guideline also prescribes the use of a lifestyle coaching app. Such normalization would vastly increase adoption – healthcare providers would then drive engagement by prescribing and monitoring the app usage just as they do medications. Reimbursement is crucial here: payers in the future may reimburse digital interventions if they prove to reduce costs (as some have begun doing, e.g., in Germany and also some U.S. employer plans). If an app can demonstrate it lowers HbA1c by a significant amount or keeps patients out of the hospital, insurers have incentive to cover it. Pharma might even build outcome-based contracts for drugs that include the app’s impact (for instance, the medication’s reimbursement could be tied to outcomes that are partly achieved through the app’s effect on adherence and behavior).

• Omnichannel and Ecosystem Integration: The future of pharma marketing is omnichannel – seamlessly integrating interactions across multiple channels (in-person, email, app, phone, etc.). Apps will not exist in isolation; they’ll be one part of a continuum of care and communication. We can expect pharma to link apps with other services: patient support hotlines, nurse outreach programs, virtual assistants, and even social care. For example, an adherence app might be integrated so that if a patient flags a side effect or a concern in the app, it triggers a live nurse to call them, or it creates a report that a field reimbursement specialist might use to help with insurance issues. On the HCP side, apps may integrate with pharma’s CRM systems – for instance, an HCP’s interactions with an app (like reading educational content or using a sample ordering feature) can inform what information a sales rep or medical science liaison provides next, creating a more personalized experience for the physician. Essentially, data from apps will feed into how pharma designs both marketing and patient support interventions in a coordinated way. The outcome should be a more cohesive experience: patients won’t have to separately manage a website, an app, and phone calls – the systems will share data so the patient doesn’t have to repeat themselves and so that each channel reinforces the other. This requires strong data interoperability (likely leveraging APIs and common standards like FHIR for health data). In the near future, a doctor might “e-prescribe” a pharma app directly from their electronic health record system, sending an invitation to the patient. The patient uses the app, which then can send a summary back to the EHR. Such tight integration would significantly remove barriers to use and ensure the app’s role is cemented in the care process.

• Augmented Reality (AR) and Virtual Reality (VR) for Engagement: Another innovation area is using AR/VR to enhance patient or HCP engagement. For patients, AR could be used within apps for things like interactive education – for example, pointing your phone camera at your injection site and the app shows an AR overlay of where and how to inject (some companies have prototyped AR guides for self-injection training). VR might be used for pain management or anxiety reduction (there are VR programs that distract patients during procedures or help with phobia therapy). Pharma could incorporate these into their support offerings. For HCPs, AR is being used for things like visualizing MOA (mechanism of action) of drugs in 3D or simulating patient cases. While these might not be “apps” in the traditional sense, they could be features within an app or related tools. For instance, an HCP app might have an AR mode where scanning a poster or brochure triggers a 3D model of a molecule binding to a receptor, which is more engaging than static images. Future sales reps might use AR on iPads for immersive product demos. These technologies can create a “wow” factor and drive deeper engagement by making complex information more accessible and memorable.

• Advanced Analytics and Real-World Evidence Generation: With more data streaming from apps (and other digital sources), pharma will increasingly use advanced analytics to generate insights. One future aspect might be using app data for personalized medicine. For example, analyzing patterns of symptom data and response could identify subgroups of patients who respond better to a drug, thereby guiding more targeted use of therapies (and potentially new indications or combination approaches). Real-world evidence collected via apps could even support regulatory submissions or label expansions if rigorous enough. As AI techniques like machine learning are applied to the big datasets from apps, we might discover new adherence risk factors or early warning signs of complications that can then be integrated back into the app as features. For the individual user, this means the app experience might continuously improve and personalize over time (e.g., “Patients like you often benefit from X – here’s a suggestion…”). For broader healthcare, it means pharma can demonstrate value with data – potentially influencing guidelines or payer policies by showing, say, “our app + drug reduced hospitalizations by 30% in heart failure by intervening early when weight rose, as flagged by the app.”

• Consolidation and “Super Apps”: Currently, many pharma maintain separate apps for each product or purpose. In the future, we may see consolidation into more comprehensive platforms. Patients with multiple conditions don’t want a different app for each drug. Pharma might collaborate or create joint platforms that manage the whole patient rather than one therapy. Alternatively, big tech players or healthcare systems might offer platforms into which pharma can plug their modules. If, for example, Apple Health or Google’s health offerings become central, pharma may distribute their app’s functionality through those (some of this already occurs via healthkit integrations). The concept of a “super app” for health (akin to WeChat for social/commercial in China, but for healthcare) could emerge – one app to manage all health needs, which could be run by a consortium of stakeholders. Pharma data would feed into it, and engagement might be higher because the app is deeply integrated into daily life, not just when taking one drug. While this is speculative, the underlying trajectory is toward integration rather than silos – the patient shouldn’t have to juggle 10 apps; they want one cohesive experience. Pharma will need to decide whether to be a leader in building those ecosystems or adapt to integrating with others’ ecosystems.

• Regulatory and Policy Support: On the horizon, we might see regulatory bodies further encouraging digital tools as part of care. The FDA is actively developing its Digital Health Center of Excellence and refining guidance on Software as a Medical Device. In a few years, regulatory approval of a new drug might commonly involve an associated app or digital tool strategy in the approval package (perhaps not mandated, but considered a best practice for certain disease areas, like an FDA guidance could recommend including an adherence strategy for drugs with known adherence challenges). This could formalize what is now just competitive advantage into a standard of care. Furthermore, healthcare payers might start expecting pharma to include these tools and even price therapies based on outcomes that presume use of an app. For example, a payer might say, “We’ll reimburse Drug X at premium only if your companion app is used to ensure patients actually benefit; otherwise, we see too much non-adherence waste.” While such models are nascent, value-based care trends indicate a focus on ensuring medications are used effectively, and digital can be the enabler.

• Global Health and Emerging Markets: In emerging markets, mobile apps (and generally mobile health) are leapfrogging traditional healthcare infrastructure in some ways. Pharma might innovate engagement models there – for instance, WhatsApp-based adherence programs or SMS integrated apps for areas with lower smartphone penetration. The future could see pharma apps that are lighter (to run on basic phones) or that integrate with popular messaging platforms to reach more people. Also, gamification and rewards might take culturally specific forms (in some countries, community-based competitions or integrating with social networks could drive engagement). Pharma will likely tailor their digital engagement strategies country by country more, using the app as a flexible tool that can incorporate local languages, incentives (maybe mobile airtime rewards?), and partnerships (with local telehealth providers or pharmacies).

In summary, the future of app engagement in pharma marketing is poised to be more intelligent, more integrated, and more impactful. We will see apps that not only remind patients to take pills, but actively adjust to patients’ lives, predict their needs, and become a standard part of therapy. The pharma company of the future might consider itself as much a data and software provider as a medicine manufacturer. This will require new skill sets, collaborations with tech companies, and a focus on user-centric design like never before.

One thing is clear: digital innovation will continue to reshape how pharma interacts with both patients and providers. Those companies that successfully harness these innovations – by providing truly helpful and engaging apps – stand to improve patient outcomes and strengthen their position in an increasingly competitive and value-driven healthcare environment pmlive.com geneticdigital.co.uk.

Conclusion

Mobile apps have emerged as a crucial component of pharmaceutical marketing and patient support strategies. As detailed in this report, pharma companies are leveraging apps to extend care beyond the pill, seeking to improve medication adherence, enhance patient engagement, and provide value-added services to both patients and healthcare professionals. We have explored how apps are being used (from patient adherence tools and disease education platforms to HCP engagement portals), the trends fueling their adoption (such as the COVID-accelerated digital health boom and the rise of reimbursable digital therapeutics), and the strategic objectives pharma pursues through these digital initiatives (better outcomes, brand loyalty, data insights, and differentiation).

Effective engagement strategies – including gamification, personalization, community-building, and device integration – have been identified as keys to a successful app. Metrics like active user retention, session frequency, and improvements in clinical outcomes are used to gauge impact, and early successes show that well-designed apps can indeed boost adherence rates and even clinical metrics. However, we also underscored the challenges and barriers that persist: regulatory and privacy requirements, difficulties in driving user adoption and long-term use, and the need to integrate apps into clinical practice and healthcare systems. Regulatory and compliance considerations, from FDA guidance to GDPR rules, form a necessary framework ensuring safety and trust, and pharma companies must diligently navigate these to deploy apps responsibly.

The case studies examined – such as Roche’s MySugr diabetes app, Propeller’s inhaler sensor platform, and various others – illustrate both the potential and the pitfalls of pharma apps. They demonstrate that when apps deliver real value (e.g., simplifying disease management or proving efficacy in studies), patients and providers will embrace them. They also highlight that partnership and innovation are often essential (pharma isn’t doing this alone but collaborating with tech experts). On the other hand, some initiatives have faced setbacks due to user acceptance issues or unsustainable models, offering lessons for future efforts.

Looking ahead, the future of app engagement in pharma is bright and dynamic. We anticipate more intelligent apps powered by AI that provide personalized coaching, wider integration with wearables and health data ecosystems, and a blurring line between traditional therapies and digital therapeutics. Pharma apps may become not just companion pieces but core parts of treatment, with doctors prescribing them and payers reimbursing them similarly to medications. Innovations like augmented reality for patient education or AI chatbots for 24/7 support are likely to further enrich the user experience.

To succeed in this evolving landscape, pharmaceutical companies will need to remain patient-centric and data-driven. That means continuously updating apps based on user feedback and real-world evidence, maintaining the highest standards of privacy and ethical conduct, and proving through data that their digital tools genuinely improve outcomes. The competitive advantage will lie with those who can seamlessly integrate these digital offerings with their core products and the broader healthcare workflow, thereby delivering a cohesive solution to patients and providers.

In conclusion, app engagement in pharmaceutical marketing is no longer a novelty – it is an essential pillar of how pharma can enhance the value of its therapies in a digital age. By educating patients, supporting adherence, facilitating clinician connections, and collecting valuable insights, mobile apps represent a powerful channel to improve healthcare delivery and outcomes. The path is not without challenges, but the continued convergence of health and technology promises exciting opportunities. As pharma companies innovate and stakeholders increasingly embrace digital health, we can expect these apps to play an ever more significant role in chronic disease management, patient empowerment, and the overall marketing and service model of the life sciences industry pmlive.com deloitte.com.

Sources:

1. Matveeva, O. et al. (2023). The business case for Patient Companion Solutions deloitte.com deloitte.com. Deloitte Perspectives.

2. Deloitte Switzerland (2023). Patient Companion Solutions – Value creation models deloitte.com digitalya.co.

3. Lightley, D. (2024). Beyond the Pill: The Power of Pharma Companion Apps pmlive.com pmlive.com. Genetic Digital Insights.

4. Genetic Digital (2024). Branded Companion Apps – Features and Benefits geneticdigital.co.uk geneticdigital.co.uk.

5. Digitalya (2023). Pharma companion apps – essential features for engagement digitalya.co digitalya.co.

6. Digitalya (2023). Gamification and rewards increase adherence digitalya.co.

7. Revolve Healthcare (2024). Digital companion apps – patient engagement drivers revolve.healthcare revolve.healthcare.

8. IQVIA Institute (2024). Digital Health Trends 2024 drugstorenews.com drugstorenews.com.

9. ZS Associates (2021). Patient retention on medication – statistics zs.com.

10. McKinsey & Co. (2020). Improving patient adherence through data insights mckinsey.com.

11. PMLiVE (2024). Pharma companion apps overview pmlive.com pmlive.com.

12. Telecare Aware (2018). Why chronic disease apps haven’t been widely used telecareaware.com telecareaware.com.

13. Indegene (2022). Case Study: HCP engagement platform results indegene.com.

14. HopeLab Research (2008). Re-Mission Impact Study digitalya.co (via Deloitte).

15. Matveeva, O. et al. (2023). MySugr case study – Roche Diabetes deloitte.com deloitte.com.

16. Levy, S. (2024). IQVIA Digital Health Trends – key findings drugstorenews.com drugstorenews.com.